# IMscin002 (NCT05171777)

> A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: subcutaneous atezolizumab
- Indication: non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05171777
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Non-small Cell Lung Cancer
- Interventions: Atezolizumab
- Enrollment: 179
- Primary outcome: Percentage of Participants Who Preferred Atezolizumab SC to Atezolizumab IV Assessed Using Patient Preference Questionnaire (PPQ)

## Indexed commentary on IMscin002 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 posts on X
- 4 YouTube videos
- 3 podcast episodes

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=imscin002-nct05171777

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05171777", "email": "<work email>"}; the inbox owner confirms by the emailed link.